Randomized Phase Ii Study Of Pembrolizumab (P) Alone Versus Pegilodecakin (Peg) In Combination With P As First-Line (1l) Therapy In Patients (Pts) With Stage Iv Non-Small Cell Lung Cancer (Nsclc) With High Pd-L1 Expression (Cypress 1).
JOURNAL OF CLINICAL ONCOLOGY（2020）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要